CSC became one of 2 local companies in Shanghai who is granted with permit license of dealing with anesthetic and psychoactive drugs.
CSC's wholly-owned subsidiary (SHHY India Private Limited) established in Hyderabad
CSC was renamed as China Chinopharma Ltd.
CSC set up its Indian office, and completed supplementary notice of 55 APIs in this year.
CSC’s sales volume exceeds 29 million US dollars.
CSC published Business Guide to China’s Pharmaceutical Market- India Edition.
CSC hosted the CPHI India-China Pharmaceutical Business Conference under the request of Consulate General of India in Shanghai.
CSC built its own modern laboratory. CSC was the first company doing so among all Chinese pharmaceutical trading companies, which can meet urgent requirements both from suppliers and customers.
CSC audited Cadila Pharmaceutical Ltd with a Chinese FDF customer and assumed all costs. CSC was the first company doing so among all Chinese pharmaceutical distribution companies.
The merger of two companies were completed and the company was renamed as China Shanghai Chinopharma Ltd (CSC) and GSP certificate was granted to CSC by Shanghai FDA .
CSC set up registration department with its own staffs which is responsible for MA registration solely. CSC was the first company doing so among all Chinese pharmaceutical trading companies.
CSC introduced the business cooperation model of entering China market with zero risk to Indian drug manufacturers, and CSC is the first company who raised this model in the pharmaceutical business between India and China.
With this business model, CSC chooses the products and bears all MA fees.
CSC successfully introduced a commercial theory into Indian pharmaceutical industry that exclusivity is the sole business mode that suits the China market, CSC is the first company who raised this theory in the pharmaceutical business between India and China.
Dr.Reddy's Laboratories Ltd (DRL), appointed CSC as its exclusive sales agent for Dextromethorphan HBr for 3 years in China market including MNCs. From 2003 to 2005, the volume of Dextromethorphan HBr that CSC purchased from DRL was over 10 times than the total volume that DRL had sold in the past 3 years in China. Meanwhile, it made Wockhardt’s sales volume shrink to one third of DRL.
At present, most of Indian pharmaceutical companies operate the Chinese market by appointing exclusive agency, such as Alembic, Piramal, Wockhardt, Zydus and so on.
In the same year, CSC was approved by 'Good Supply Practice' (called 'GSP' in short).
CSC was founded through a capital injection from China Worldbest Group Co., Ltd.
CSC obtained 'License for pharmaceutical trading' issued by CFDA.